Rituximab as Single Agent in Primary MALT Lymphoma of the Ocular Adnexa

Table 2

Results by Rituximab in OAL (review of the literature).

	Patients	Diagnosis	Clinical stage	Rituximab dose	Outcome	Longer follows-up (months)
Nückel et al. [36]	2	Relapsed after RT	IE	375 mg/mq once weekly for 4 wks.	1 CR; 1 RP	30 and 32
Ferreri et al. [37]	8	5 newly diagnosed; 3 relapses	IE (4); IV (4)	375 mg/mq once weekly for 4 wks.	3 CR; 2 PR; 2 PD; 1 SD	Not available
Tuncer et al. [39]	10	Newly diagnosed	IE	375 mg/mq iv every 3 wks. for 6–8 cycles	36% CR; 64% PR	31
Zinzani et al. [40]	1	Newly diagnosed	IE	375 mg/mq once weekly for 4 wks.	CR	—
Sullivan et al. [55]	8	Newly diagnosed	—	375 mg/mq once weekly for 4 wks.	5 CR, 2 PR; 1 No Res	32
Heinz et al. [56]	1	Newly diagnosed		375 mg/mq once weekly for 4 wks.	CR	—
Mino et al. [57]	10	Newly diagnosed	I-IIE	375 mg/mq every 4 wks. for 6–8 cycles	10 CR
Present study	6	Newly diagnosed	IE	375 mg/mq every 3 wks. for 6 cycles + maintenance for 2 years	4 CR; 2 PR	34